Aspen Pharmacare to sell major Asia Pacific operations to BGH Capital for USD1.59B

AUSTRALIA—South African pharmaceutical giant Aspen Pharmacare has announced plans to sell its major Asia Pacific assets to Australian private equity firm BGH Capital for A$2.37 billion (USD1.59 billion).

The transaction excludes the company’s operations in China and represents a significant strategic shift for South Africa’s largest pharmaceutical producer.

The sale came about following an unsolicited offer from BGH Capital, which focuses on investments in Australia and New Zealand.

While Aspen had not initially planned to divest these assets, company leadership decided to move forward after carefully evaluating the proposal.

The deal marks a pivotal moment for Aspen, as the Asia Pacific region represented its first expansion beyond South African borders, beginning with operations in Australia and New Zealand.

According to the company’s statement, the divestiture will enable Aspen to concentrate its resources on producing GLP-1 drugs, which have emerged as a critical area of growth in the pharmaceutical industry.

The proceeds from the sale will also help reduce the company’s debt burden and strengthen its capital position, supporting broader turnaround initiatives currently underway.

Aspen CEO Stephen Saad emphasized the strategic benefits of the transaction.

He described the deal as aligned with the company’s long-term objectives and said it represents a compelling proposition for both the organization and its shareholders.

Saad also provided reassurance regarding the workforce, noting that existing employment conditions for staff in the affected businesses are expected to continue normally under the new ownership.

The company has been positioning itself to capitalize on the rapidly expanding weight-loss drug market.

As a marketer for Eli Lilly’s highly successful diabetes and obesity medication Mounjaro, Aspen has been working to offset challenges arising from contractual disputes and increasing operational costs.

The weight-loss drug sector has experienced explosive growth in recent years, making it an attractive area for pharmaceutical companies seeking new revenue streams.

Beyond the Asia Pacific sale, Aspen is implementing additional cost-cutting measures across its operations.

The company plans to restructure its manufacturing facilities in France and South Africa that produce sterile drugs, which must be entirely free from living microorganisms.

These facility optimizations are designed to improve operational efficiency and reduce expenses.

The announcement follows a difficult financial period for Aspen, whereby in September, the firm reported an annual loss of R1.1 billion (USD66 million) for its fiscal year.

The company attributed this loss primarily to substantial asset impairments stemming from ongoing contractual disputes related to mRNA products.

The Asia Pacific assets being sold encompass operations in Hong Kong, Taiwan, Malaysia, and the Philippines.

These markets have been significant contributors to Aspen’s overall performance, accounting for 18% of the company’s total revenue and 26% of its core profit for the year ending June 30, 2025.

Despite their substantial contribution, the company believes divesting these assets will ultimately position it more favourably for future growth and financial stability.